Expert Interview
Anaptys Bio's(ANAB) ANB019 (imsidolimab) in Acne Vulgaris -ACORN Phase 2 data due 1H 2022
Ticker(s): ANABDermatologist with clinical research experience
How do you regard the scientific rationale of IL36R blockage in acne vulgaris?
Added By: a832iWhat are the implications of the PPP failure of spesolimab and imsidolimab for the probability of success rate for ACORN?
Added By: a832iDo you think the ACORN trial has a suitable design to show the potential of imsidolimab in acne vulgaris?
Added By: a832iHow would you rate the potential of imsidolimab for the treatment of acne vulgaris? Would you use it?
Added By: a832iDo you think other biologics would be better suited for the treatment of acne? What will be the benchmark in respect to efficacy for ACORN?
Added By: a832iWhat are the requirements regarding price and safety for a biologic to be used for acne patients?
Added By: a832iDo you think the ACORN data will provide a read-through for the hidradenitis suppurativa in 2H 2022?
Added By: a832iAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
